Natco Pharma Ltd Q3 FY2024 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/m469hjlyz0cli451weneijix.pdf

Key Takeaways


The Revlimid Trajectory

Rajeev Nannapaneni: "Every company goes through a cycle where you make money on one product, and it falls away. And I think the way you need to judge a company is what pipeline do you have and what's going to be the next big product."

Pipeline: The Next Big Products


Non-Pharma Bets: Crop Health & Agrochem


Capital Allocation: Cash, M&A, and Returns

Rajeev Nannapaneni: "I have very high expectations. I think we usually look for higher teens or 20% is my expectation. I don't like doing 10%, 12% transactions. I'm not a big fan of those because my hurdle has been so high, it's been difficult to do transactions. But I think we are sharp and we're patient."

Base Business & Operational Updates

Rajeev Nannapaneni: "The only thing going to make money in this business, one, you have complex generics, difficult-to-do products. Two, we have global reach. And you have a steady, branded generic business. I think these are the 3 ways you can make money. And I think out of these 3, you need to get at least 1 -- at least 2 things right and I think that's what will get you home."

Guidance & Commitments

CommitmentSpecificsTimeline
FY24 PATExpect to go past ₹1,200 crores (higher end of earlier ₹1,000-1,200 crores guidance)FY24 full year
FY24 SalesExpecting a little less than ₹4,000 croresFY24 full year
Tax rateExpectation of around 16-17% continuingGoing forward
Crop Health revenueGuidance range ₹150-200 crores, likely on the lower sideFY24
U.S. pipeline deliveryAt least 2 or 3 products as interesting as semaglutide and OlaparibNext 12 months
FTF targetGrow from 3-4 to 6-7 smart FTFsNext 2 years
Oligopeptide filingHoping to get a filing throughNext 12 months
Agrochem exportsExports won't kick in; some markets opening, major markets in 2-3 years2-3 years
FY25 guidanceWill guide for March 2024; may have more clarityNext call
Revlimid quota clarityWill give more color when March numbers are availableMay

Key Metrics

MetricQ3 FY24
Consolidated total revenue₹795.6 cr, +55% YoY
Net profit (consolidated)₹212.7 cr, ~3.5x vs ₹62.3 cr in Q3 FY23
Formulation exports revenue₹605.6 cr
Formulation domestic revenue₹99.4 cr
API revenue₹46.3 cr
Crop health revenue₹14.1 cr
Revenue from all subsidiaries₹163 cr, primarily driven by Canada and Brazil
EBITDA (9 months YTD)₹1,340 cr
PAT (9 months YTD)₹1,000 cr
Capex (9 months YTD)₹282 cr
Tax rate expectation16% to 17%, expected to continue going forward
FY24 PAT expectationHoping to go past ₹1,200 cr
FY24 sales expectationA little less than ₹4,000 cr
Crop health revenue (9 months YTD)~₹110 cr
Crop health FY24 expected revenue₹150 cr to ₹160 cr, lower end of ₹150 cr to ₹200 cr guidance
Domestic formulation oncology share60% to 65% of domestic portfolio
Freight rates increase50% to 60% increase due to Red Sea disruption
Closing inventory (consol)₹675 cr as of March 31, 2023